论文部分内容阅读
目的:探讨肾移植术后患者应用雷帕霉素(Rap)为基础免疫抑制药抗排斥治疗的疗效。方法:对16例肾移植术后患者应用Rap为基础免疫抑制药治疗排斥反应,对血肌酐恢复情况、移植肾存活及副作用作回顾分析。结果:16例肾移植术后即开始用药者11例移植肾功能恢复顺利,人肾存活良好;5例术后半年以上因移植肾功能减退而转换为Rap治疗患者中有4例血肌酐升高明显减缓。结论:雷帕霉素作为基础免疫抑制药治疗肾移植术后排斥反应有较好疗效。
Objective: To investigate the effect of rapamycin (Rap) -based immunosuppressive anti-rejection therapy in patients after renal transplantation. Methods: 16 cases of renal transplant recipients with Rap-based immunosuppressive drugs in the treatment of rejection, serum creatinine recovery, graft survival and side effects for retrospective analysis. Results: In the 16 cases of renal transplant recipients, the function of transplanted kidneys in 11 cases recovered smoothly and the survival of human kidneys was good. In 5 cases, the serum creatinine level was increased in 5 of 5 cases who were converted to Rap after transplantation for more than half a year Obviously slow down. Conclusion: Rapamycin as a basic immunosuppressive drug is effective in treating rejection after renal transplantation.